{"id":933,"date":"2020-12-10T15:10:31","date_gmt":"2020-12-10T10:10:31","guid":{"rendered":"http:\/\/fyut.uz\/?p=933"},"modified":"2020-12-10T15:12:09","modified_gmt":"2020-12-10T10:12:09","slug":"ozbekistonda-koronavirusga-qarshi-rekombinant-vaksinaning-uchinchi-sinov-bosqichi-boshlandi","status":"publish","type":"post","link":"https:\/\/fyut.uz\/?p=933","title":{"rendered":"O\u2018zbekistonda koronavirusga qarshi rekombinant vaksinaning uchinchi sinov bosqichi boshlandi \u00a0"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

O\u2018zbekistonda koronavirusga qarshi rekombinant vaksinaning uchinchi sinov bosqichi boshlandi \u00a0<\/strong><\/h3>\n<\/div>\n
\n

Joriy yilning 10 dekabr kuni Innovatsion rivojlanish vazirligida O\u2018zbekistonda yangi koronavirus rekombinant vaksinasi (CHO hujayra) xalqaro klinik sinovlarining III fazasi boshlanishiga bag\u2018ishlangan marosim o\u2018tkazildi.<\/h4>\n

Innovatsion rivojlanish vazirligi xabariga ko\u2018ra<\/a>, Innovatsion rivojlanish hamda Sog\u2018liqni saqlash vazirliklari tomonidan Xitoy Fanlar akademiyasi Mikrobiologiya institutining ishlanmasi asosida Zhifei Longcom Biopharmaceutical Co., Ltd kompaniyasi ishlab chiqqan koronavirusga qarshi vaksinaning uchinchi bosqich klinik sinovlarini o\u2018tkazish ishlari boshlandi.<\/p>\n

\"\"<\/p>\n

Xitoydagi O\u2018zbekiston elchixonasi yordamida O\u2018zbekistonga Zhifei kompaniyasi tomonidan 6000 dona sinov vaksinasi (50 foizi haqiqiy vaksina, 50 foizi platsebo), 12 ming dona PZR testlar, 8 ming dona antitanalarni aniqlovchi testlar hamda barcha ishlatiladigan yordamchi materiallar (shprits, niqob, ko\u2018zoynak, krioprobirkalar, homiladorlik testlari) olib kelindi.<\/p>\n

Klinik sinovlarni o\u2018tkazish uchun jami 5 ming nafar ko\u2018ngillilar tanlab olindi. Jarayonning etik jihatlarini e’tiborga olgan holda ko\u2018ngillilarning shaxsi oshkor qilinmasligiga kelishildi.<\/p>\n

\"\"<\/p>\n

O\u2018z navbatida, Zhifei Longcom Biopharmaceutical Co. Ltd kompaniyasining 8 nafar mutaxassisi Innovatsion rivojlanish vazirligi huzuridagi Ilg\u2018or texnologiyalar markazi hamda Sog\u2018liqni saqlash vazirligidagi Virusologiya ilmiy-tadqiqot instituti xodimlari bilan birgalikda sinov o\u2018tkaziladigan poliklinikalari vrach va hamshiralari uchun vaksinatsiya tadbirlarini amalga oshirish bo\u2018yicha treninglar o\u2018tkazdi.<\/p>\n

Zhifei Longcom Biopharmaceutical Co. Ltd kompaniyasi tomonidan ishlab chiqilgan va hozirda klinik sinovdan o\u2018tishi boshlanadigan vaksina koronavirus yuza antigenining genetik-muhandislik oqsili bo\u2018lib, u adenovirus hamda inaktivlashgan vaksina turlari bilan taqqoslanganda yuqori darajada xavfsiz hisoblanadi. Ya’ni rekombinant oqsil ko\u2018rinishidagi vaksina virusning bir bo\u2018lagini yuqori texnologiyalar asosida sun’iy ko\u2018paytirib olishga asoslangan. \u00a0Genetik-muhandislik oqsili zararlangan organizmda aynan unga qarshi antitanachalar ishlab chiqaradi.<\/p>\n

Ushbu vaksina I va II faza klinik sinovlarda nisbatan yuqori xavfsizlik profiliga egaligini namoyon etdi. Innovatsion rivojlanish vazirligi rahbariyatining 20 nafar ko\u2018ngilli oila a’zolari Xitoydan olib kelingan rekombinant vaksina bilan birinchi dozada emlandi, deyiladi vazirlik xabarida.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

O\u2018zbekistonda koronavirusga qarshi rekombinant vaksinaning uchinchi sinov bosqichi boshlandi \u00a0 Joriy yilning 10 dekabr kuni Innovatsion rivojlanish vazirligida O\u2018zbekistonda yangi koronavirus rekombinant vaksinasi (CHO hujayra) xalqaro klinik sinovlarining III fazasi boshlanishiga bag\u2018ishlangan marosim o\u2018tkazildi. Innovatsion rivojlanish vazirligi xabariga ko\u2018ra, Innovatsion rivojlanish hamda Sog\u2018liqni saqlash vazirliklari tomonidan Xitoy Fanlar akademiyasi Mikrobiologiya institutining ishlanmasi asosida Zhifei Longcom […]<\/p>\n","protected":false},"author":1,"featured_media":936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"_links":{"self":[{"href":"https:\/\/fyut.uz\/index.php?rest_route=\/wp\/v2\/posts\/933"}],"collection":[{"href":"https:\/\/fyut.uz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fyut.uz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fyut.uz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fyut.uz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=933"}],"version-history":[{"count":3,"href":"https:\/\/fyut.uz\/index.php?rest_route=\/wp\/v2\/posts\/933\/revisions"}],"predecessor-version":[{"id":939,"href":"https:\/\/fyut.uz\/index.php?rest_route=\/wp\/v2\/posts\/933\/revisions\/939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fyut.uz\/index.php?rest_route=\/wp\/v2\/media\/936"}],"wp:attachment":[{"href":"https:\/\/fyut.uz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fyut.uz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fyut.uz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}